Related Experiment Videos
Chlorpromazine-induced immunopathy: progressive increase in serum IgM
S Zucker1, H M Zarrabi, W H Schubach
1Department of Medicine, Veterans Administration Medical Center, Northport, NY 11768.
Medicine
|March 1, 1990
Summary
Long-term chlorpromazine (CPZ) treatment can cause immune system issues. Patients with elevated IgM levels should switch to alternative antipsychotics to prevent serious health complications.
Area of Science:
- Immunology
- Pharmacology
- Psychiatry
Background:
- Long-term chlorpromazine (CPZ) therapy is linked to asymptomatic immune system abnormalities, including antinuclear antibodies and elevated IgM.
- The study aimed to characterize the natural history of chlorpromazine-induced immunopathy.
Observation:
- A prospective study compared continuing CPZ versus switching to haloperidol in schizophrenic patients with CPZ-induced immunopathy.
- Over 5 years, 6 of 29 patients on CPZ showed progressive IgM elevation, versus none of 14 on haloperidol.
Findings:
- While no lupus-like syndrome developed, one patient on CPZ for over 15 years developed Waldenström macroglobulinemia.
- Another patient developed immune thrombocytopenia, highlighting potential serious sequelae of prolonged CPZ exposure.
- Progressive elevations in serum IgM were observed in a subset of patients continuing CPZ therapy.
Implications:
- Prolonged immune system stimulation by CPZ may lead to severe conditions like macroglobulinemia and immune thrombocytopenia.
- Patients exhibiting increased serum IgM during CPZ treatment should be considered for a switch to alternative antipsychotic medications.
- Monitoring IgM levels in patients on long-term chlorpromazine therapy is crucial for early detection of potential immunopathy.